[Assessment of efficacy and tolerability of mirtazapine treatment of patients with depression].
The paper presents results of the study on the efficacy and tolerability of mirtazapine treatment of patients with depression. The study was open and conducted in three centers. 65 out- and in-patients with diagnosis of depression was included. 50% reduction of the score in the HAM-D scale was obtained in 57%, according to MADRS scale--in 61% patients. Side effects were reported in 49% patients. The most frequent side effects were: drowsiness, fatigue, anxiety, sleepiness, weight increase, headache. The results of the study are comparable with other mirtazapine studies.
Beszłej
Aleksander
A
Katedra i Klinika Psychiatrii AM we Wrocławiu.
Grzesiak
Magdalena
M
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000929:Antidepressive Agents, Tricyclic / Q000008:administration & dosage* / Q000009:adverse effects*; D001007:Anxiety / Q000139:chemically induced; D003866:Depressive Disorder / Q000188:drug therapy*; D005221:Fatigue / Q000139:chemically induced; D005260:Female; D006261:Headache / Q000139:chemically induced; D006801:Humans; D008297:Male; D008803:Mianserin / Q000008:administration & dosage* / Q000009:adverse effects* / Q000031:analogs & derivatives; D008875:Middle Aged; D000078785:Mirtazapine; D012892:Sleep Deprivation / Q000139:chemically induced; D012894:Sleep Stages / Q000187:drug effects; D015430:Weight Gain / Q000187:drug effects
D000929:Antidepressive Agents, Tricyclic; D008803:Mianserin; D000078785:Mirtazapine